

# FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response...	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person ROSENWALD LINDSAY A MD		2. Issuer Name and Ticker or Trading Symbol CORONADO BIOSCIENCES INC [CNDO]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below)	
(Last) (First) (Middle) C/O CORONADO BIOSCIENCES, INC., 24 NEW ENGLAND EXECUTIVE PARK		3. Date of Earliest Transaction (Month/Day/Year) 12/19/2013		President and CEO	
(Street) BURLINGTON, MA 01803		4. If Amendment, Date Original Filed(Month/Day/Year)		6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person	
(City) (State) (Zip)		<b>Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned</b>			

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock, par value \$0.001	12/19/2013		A		1,979,346	A	\$ 0	4,638,347	D	
Common Stock, par value \$0.001								170,983	I	By Capretti Grandi LLC
Common Stock, par value \$0.001								453,822	I	By LAR Family Trusts
Common Stock, par value \$0.001								742,861	I	By Paramount Biosciences
Common Stock, par value \$0.001								100,000	I	By The Lindsay A. Rosenwald Rhode Island Irrevocable Trust U/T/A DTD 8-28-01
Common Stock, par value \$0.001								80,000	I	By The Lindsay A. Rosenwald Alaska Irrevocable Trust U/T/A DTD 8-29-01
Common Stock, par value \$0.001								720,000	I	By The Lindsay A. Rosenwald 2000 Irrevocable Trust U/T/A DTD 5-24-00
Common Stock, par value \$0.001								100,000	I	By The Lindsay A. Rosenwald Nevada Irrevocable Indenture of Trust U/T/A DTD 8-29-01

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Options to purchase Common Stock	\$ 1.37							(2)	10/05/2020	Common Stock	25,000		25,000	D	
Options to purchase Common Stock	\$ 6.25							(3)	02/10/2022	Common Stock	15,000		15,000	D	
Options to purchase Common Stock	\$ 7.42							(4)	02/07/2023	Common Stock	15,000		15,000	D	
Warrants to purchase Common Stock	\$ 6.15							(5)	(6)	Common Stock	6,798		6,798	I	By LAR Family Trusts
Warrants to purchase Common Stock	\$ 6.15							(5)	(7)	Common Stock	3,399		3,399	I	By LAR Family Trusts
Warrants to purchase Common Stock	\$ 6.15							(5)	(8)	Common Stock	850		850	I	By LAR Family Trusts

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
ROSENWALD LINDSAY A MD C/O CORONADO BIOSCIENCES, INC. 24 NEW ENGLAND EXECUTIVE PARK BURLINGTON, MA 01803	X	X	President and CEO	

## Signatures

/s/ Alexander M. Donaldson, Attorney-in-Fact	12/23/2013
Signature of Reporting Person	Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Represents a restricted stock award which vests one third when the Issuer achieves market capitalization of two, three, and four times its current market capitalization, but in no event earlier than three, four, and five years following the date of grant, respectively.

(2) One-third of the shares vested on each of October 5, 2011, 2012 and 2013.

(3) One-third of the shares will vest on each of February 10, 2013, 2014 and 2015.

- (4) One-third of the shares will vest on each of February 7, 2014, 2015 and 2016.
- (5) This warrant is fully vested.
- (6) 4,472 shares underlying this warrant expire on January 22, 2014, 835 shares underlying this warrant expire on May 28, 2014 and 1,491 shares underlying this warrant expire on June 24, 2014.
- (7) 2,236 shares underlying this warrant expire on January 22, 2014, 417 shares underlying this warrant expire on May 28, 2014 and 746 shares underlying this warrant expire on June 24, 2014.
- (8) 559 shares underlying this warrant expire on January 22, 2014, 104 shares underlying this warrant expire on May 28, 2014 and 187 shares underlying this warrant expire on June 24, 2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

POWER OF ATTORNEY

Known all by these presents, that the undersigned hereby constitutes and appoints each of Robyn Hunter, W. David Mannheim, Alexander M. Donaldson and S. Halle Vakani, and each of them acting alone, signing singly, the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or 10% or more stockholder of Coronado Biosciences, Inc. (the "Company"), Forms ID, 3, 4 and 5 (and any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "1934 Act"), and the rules promulgated thereunder; (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form ID, 3, 4 or 5 (and any amendments thereto) and to file timely such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and (3) take any other action of any type whatsoever in connection with the foregoing which in the opinion of such attorney-in-fact may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the 1934 Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms ID, 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to each of the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 19th day of December 2013.

/s/ Lindsay A. Rosenwald

-----  
Lindsay A. Rosenwald, M.D.